期刊
BIOCHEMICAL JOURNAL
卷 476, 期 -, 页码 365-374出版社
PORTLAND PRESS LTD
DOI: 10.1042/BCJ20170441
关键词
-
资金
- Daiichi-Sankyo, Ltd, Tokyo
- National Cancer Institute [5R35CA197709]
- NIH [HHSN261200800001E]
RAS proteins have traditionally been deemed undruggable, as they do not possess an active site to which small molecules could bind but small molecules that target one form of oncogenic RAS, KRAS G12C, are already in preclinical and clinical trials, and several other compounds that bind to different RAS proteins at distinct sites are in earlier stage evaluation. KRAS is the major clinical target, as it is by far the most significant form of RAS in terms of cancer incidence. Unfortunately, KRAS exists in two isoforms, each with unique biochemical properties. This complicates efforts to target KRAS specifically. KRAS is also a member of a family of closely related proteins, which share similar effector-binding regions and G-domains, further increasing the challenge of specificity. Nevertheless, progress is being made, driven by new drug discovery technologies and creative science.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据